Effects of low-molecular-weight heparin and unfractionated heparin on traumatic disseminated intravascular coagulation
Purpose: To explore the effects of unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) on traumatic disseminated intravascular coagulation (DIC).
Methods: A total of 77 cases of severe trauma (APACHE II score: 5 – 10) with DIC were collected and randomly assigned to one of three groups: LMWH treatment - 26 cases were subcutaneously injected with LMWH (75–150 units/kg/d); UFH treatment - 25 cases were subcutaneously injected with UFH (100 – 250 units/kg/d); control - 26 cases supplemented with blood coagulation factor only. Daily mortality in the intensive care unit (ICU), hospitalization time, bleeding rate, thrombin time, prothrombin time, activated partial thromboplastin time, and levels of fibrinogen, antithrombin III (ATIII), and D-dimer were recorded and analyzed.
Results: In ICU, LMWH and UFH treatments resulted in lower mortality than in the control group. In addition, hospitalization time was longer in patients treated with LMWH and UFH than in control patients. No significant differences were found between LMWH-treated and control patients in terms of bleeding rate, but UFH-treated patients had lower bleeding rates than control patients. Multifactor analysis indicate a strong relationship between ATIII levels and bleeding rate.
Conclusion: The results indicate that low-dose UFH and LMWH are effective options for the treatment of DIC.
Keywords: Trauma, Disseminated intravascular coagulation, Unfractionated heparin, Low-molecularweight heparin, Fibrinogen, Antithrombin
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.